MARKET

CRBP

CRBP

Corbus Pharmaceu
NASDAQ
2.060
-0.375
-15.40%
After Hours: 2.090 +0.03 +1.46% 19:37 11/20 EST
OPEN
2.430
PREV CLOSE
2.435
HIGH
2.480
LOW
2.010
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
12.88
52 WEEK LOW
2.010
MARKET CAP
42.14M
P/E (TTM)
-0.3358
1D
5D
1M
3M
1Y
5Y
1D
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 15.4%, Underperforms Peers
Dow Jones · 8h ago
Corbus Pharmaceuticals Holdings Inc. Stock Slides 11.3%, Underperforms Peers
Dow Jones · 1d ago
CSPC Receives $15 Mln Milestone Payment From Corbus For CRB-701 License
NASDAQ · 1d ago
Corbus Pharmaceuticals Holdings Inc. Stock Falls 8.8%, Underperforms Peers
Dow Jones · 2d ago
Corbus Pharmaceuticals Holdings Inc. Stock Falls 10.8%, Underperforms Peers
Dow Jones · 3d ago
Corbus Pharmaceuticals Holdings, Inc. Announces Phase 1b CANYON-1 Trial Data for Obesity Treatment CRB-913
NASDAQ · 4d ago
Analysts Offer Insights on Healthcare Companies: Pro-Dex (PDEX) and Corbus Pharmaceuticals (CRBP)
TipRanks · 4d ago
Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
Benzinga · 4d ago
More
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

Webull offers Corbus Pharmaceuticals Holdings Inc stock information, including NASDAQ: CRBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRBP stock methods without spending real money on the virtual paper trading platform.